A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Journal for Immunotherapy of Cancer
Alessio CortelliniClara Natoli

Abstract

Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. We conducted a retrospective study of advanced cancer patients consecutively treated with anti-PD-1/PD-L1 inhibitors, in order to compare clinical outcomes according to baseline BMI levels as primary analysis. Based on their BMI, patients were categorized into overweight/obese (≥ 25) and non-overweight (< 25). A gender analysis was also performed, using the same binomial cut-off. Further subgroup analyses were performed categorizing patients into underweight, normal weight, overweight and obese. Between September 2013 and May 2018, 976 patients were evaluated. The median age was 68 years, male/female ratio was 663/313. Primary tumors were: NSCLC (65.1%), melanoma (18.7%), renal cell carcinoma (13.8%) and others (2.4%). ECOG-PS was ≥2 in 145 patients (14.9%). PD-1/PD-L1 inhibitors were administered as first-line treatment in 26.6% of cases. Median BMI was 24.9: 492 patients (50.6%) were non-overweight, 480 patients (50.4%) were overweight/obese. 25.2% of non-overweight patients experienced irAEs of any grade, while 55.6% of overweight/obese patients (p < 0.0001). ORR was significantly h...Continue Reading

References

Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
May 14, 2008·Infectious Disorders Drug Targets·V PallottiniM Marino
Sep 11, 2008·American Journal of Physiology. Endocrinology and Metabolism·Lindsey N SutherlandDavid C Wright
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 24, 2011·Steroids·Carlos Stocco
Aug 27, 2013·Immunity·Leonid YurkovetskiyAlexander V Chervonsky
Sep 3, 2013·The Journal of Urology·B MiñanaO Serrano
Nov 22, 2014·Diabetes·Tom SeijkensEsther Lutgens
Mar 12, 2015·Frontiers in Immunology·Thea Magrone, Emilio Jirillo
Mar 27, 2015·The Proceedings of the Nutrition Society·Alessandro LavianoAlessia Mari
Apr 17, 2015·PloS One·Niloofar TaghizadehJudith M Vonk
Jul 30, 2015·JAMA Dermatology·Martina SanlorenzoSusana Ortiz-Urda
Aug 19, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sami AntounYohann Loriot
Oct 9, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Morganna Freeman-KellerJeffrey Weber
Jan 20, 2016·Acta Oncologica·Nessn H AzawiUNKNOWN Academy of Geriatric Cancer Research (AgeCare)
Jul 30, 2016·Vaccines·McKay Mullen, Ruben Rene Gonzalez-Perez
Aug 1, 2016·Current Oncology Reports·Hannah LennonAndrew G Renehan
Sep 8, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurence AlbigesToni K Choueiri
Sep 25, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shunsuke TeraokaKeisuke Tomii
Dec 1, 2017·Current Pathobiology Reports·Benedicte F JordanPatrice D Cani
Dec 17, 2017·Oncotarget·Andrea BotticelliPaolo Marchetti
May 21, 2018·The Lancet Oncology·Fabio ConfortiAron Goldhirsch
Aug 23, 2018·Urologic Oncology·Peter J GoebellUNKNOWN RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma)

❮ Previous
Next ❯

Citations

Jul 3, 2019·Current Oncology Reports·Allison Betof Warner, Jennifer L McQuade
Aug 8, 2019·Current Opinion in Supportive and Palliative Care·Davide BroccoAntonino Grassandonia
Nov 7, 2019·Journal for Immunotherapy of Cancer·David J PinatoMark Bower
Nov 16, 2019·Journal of Translational Medicine·Alessio CortelliniPaolo A Ascierto
Apr 30, 2020·Immunotherapy·Carmine Finelli
Apr 11, 2020·Journal for Immunotherapy of Cancer·Carla V Rothlin, Sourav Ghosh
May 8, 2020·Immunotherapy·Dmitrii ShekGolo Ahlenstiel
Jun 19, 2020·Cancers·Lorey K SmithKaren E Sheppard
May 27, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·I KrakowskiH Eriksson
Jul 16, 2020·The Journal of Clinical Endocrinology and Metabolism·Rena PollackRivka Dresner-Pollak
Sep 2, 2020·Expert Review of Anticancer Therapy·Friedlaender Alex, Addeo Alfredo
Aug 6, 2019·Frontiers in Oncology·Flora Sánchez-JiménezVíctor Sánchez-Margalet
Feb 7, 2020·Journal of Cancer Research and Clinical Oncology·Kazuki TakadaMasaki Mori
Apr 1, 2020·Frontiers in Immunology·Youhai JiangHongyang Wang
May 20, 2020·Cancers·Matthew J WoodallSarah L Young
Oct 28, 2019·Oncoimmunology·Sara VerduraJavier A Menendez
Apr 5, 2020·Cancers·Michael F ColemanStephen D Hursting
Apr 30, 2020·Lung Cancer Management·Chung-Shien LeeNagashree Seetharamu
Aug 23, 2020·International Journal of Molecular Sciences·Antonio Pérez-PérezVíctor Sánchez-Margalet
Oct 8, 2020·Reviews in Endocrine & Metabolic Disorders·Marco GalloM C Zatelli
Nov 6, 2020·Journal of the National Cancer Institute·Giuseppe FlorisChristine Desmedt

❮ Previous
Next ❯

Software Mentioned

MedCalc

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Related Papers

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
Didier Silveira Castellano FilhoFernando Monteiro Aarestrup
© 2022 Meta ULC. All rights reserved